

DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR REDUCING CARDIOVASCULAR MORBIDITY AND MORTALITY IN

	PREDIA	BETIC PATIENTS AND	PATIENTS WITH TYPE 2 DIABETES	
	and the specification of wh (check one)	was filed on and was amended was described a	as U.S. Application Number (if applicable). nd claimed in PCT Int'l Application Number (if any).	
	I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.			
	I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:			
Foreign Priority:	Number	Country	Day/Month/Year Filed	
Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed	
\boxtimes	I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provision application(s) listed below:			
	60/439,941 Number	January 14, 2003 Filing Date		
	I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United Sapplication(s) or international application designating the United States listed below and, insofar as the signature of each of the claims of this application is not disclosed in the prior United States application in the material by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to distinformation which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 became available between the filling date of the prior application and the national or PCT international filling date application.			
	Application Serial No.	Filing Date	Status (Patented, Pending)	
and belief ar and the like	e believed to be true; and f so made are punishable by	further that these statements r fine or imprisonment, or bo	wledge are true and that all statements made on information is were made with the knowledge that willful false statements of the under Title 18, United States code §1001, and that such or any patent issued thereon.	
Inventors(s):	Additional names	and signatures are attached		
1. Full name: <u>I</u>	Ralf ROSSKAMP		2. Full name: Hertzel GERSTEIN	
Signature:			Signature:	
			Date:	
Country of Citizenship: Germany			Country of Citizenship: Canada	
	adstone, New Jersey (City and State/City and Coun		Residence: Hamilton, Ontario	
			(City and State/City and Country only)	
P. O. Address:	2 Brynwood Court		P. O. Address: 5 Dromore Crescent	
	Gladstone, New Jersey (J7934	Hamilton, Ontario L8S 4A8	



3. Full name:	— 4. Full name:	
Signature:	Signature:	
Date:		
Country of Citizenship:	Country of Citizenship:	
Residence:(City and State/City and Country only)	Residence:(City and State/City and Country only)	
(City and State/City and Country only) P. O. Address:		
5. Full name:	6. Full name:	
Signature:	Signature:	
Date:		
Country of Citizenship:		
Residence:	Residence:(City and State/City and Country only)	
(City and State/City and Country only)	(City and State/City and Country only)	
P. O. Address:	P. O. Address:	

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. USAV2003/0012 US NP